biostudies-literatureWagemann ONCATS NIH HHSNIA NIH HHSNIMH NIH HHS582-593https://www.ebi.ac.uk/biostudies/studies/S-EPMC11059071biostudies-literatureUnknown81(6)<h4>Importance</h4>Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are largely unknown in dominantly inherited Alzheimer disease (DIAD).<h4>Objective</h4>To investigate longitudinal biomarker changes of synaptic dysfunction, neuroinflammation, and neurodegeneration in individuals with DIAD who are receiving antiamyloid treatment.<h4>Design, setting, and participants</h4>From 2012 to 2019, the Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU-001) study, a double-blind, placebo-controlled, randomized clinical trial, investigated gantenerumab and solanezumab in DIAD. Carriers of gene variants were assigned 3:1 to either drug or placebo. The present analysis was conductedJAMA neurologyDownstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.PMC11059071P30 AG066530R56 AG053267U01 AG079850UL1 TR001863U01 AG042791R01 AG046179P30 AG062429R01 AG053267R01 AG062268R01 MH120794Fox NCBrooks WSDominantly Inherited Alzheimer Network–Trials UnitShi XScelsi MAStauber JWagemann ONicklaus JLaske CMasters CCoalier KAMummery CJHerries EOkhravi HRAllegri RFDaniels AJXu JRamirez LGordon BACruchaga CMartins RLah JJXu XCash DMJohnson ECBChhatwal JMarsh JHornbeck RSalloway SMcKay NProctor NKCourtney LSims JRRoberson EDGremminger EKoudelis DSupnet-Bell CMassoumzadeh PHuey EDJerome GRyan NSMendez PCKeefe SPerrin RJSimmons AKuder-Buletta EVоglein JRosa-Neto PIkeuchi THoltzman DMAguillon DIkonomovic SSchofield PRBarthelemy NMcCullough AHassenstab JJHofmann AJucker MYaari RRizzo JGauthier SNoble JMFarlow MRDay GSFagan AMNadkarni NKWang GBateman RJBechara JARoedenbeck YGraff-Radford NRNiimi YBerman SBBaker BGraber-Sultan SObermueller USeyfried NTWang QGalasko DKarch CMvan Dyck CHLlibre-Guerra JRingman JMLee JHChen CLi YChen APicarello DMFlores SXiong CMinton MRenton AEPariente JLu RLiu HHsiung GRFranklin EHoldridge KCBittner TSuzuki KStout SScott JKasuga KMori HPulizos CIbanez LSt George-Hyslop PGoate AMJackson KVazquez SClifford DBJoseph-Mathurin NLevey AISmith HRoh JHMcDade EMorris JCSabaredzovic ESmith JAschenbrenner AJLevin JSurace ESantacruz AMMancini MSanchez-Valle RAndersen SWJarman SBenzinger TLSLopera FLeon YMfalseDownstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.<h4>Importance</h4>Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are largely unknown in dominantly inherited Alzheimer disease (DIAD).<h4>Objective</h4>To investigate longitudinal biomarker changes of synaptic dysfunction, neuroinflammation, and neurodegeneration in individuals with DIAD who are receiving antiamyloid treatment.<h4>Design, setting, and participants</h4>From 2012 to 2019, the Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU-001) study, a double-blind, placebo-controlled, randomized clinical trial, investigated gantenerumab and solanezumab in DIAD. Carriers of gene variants were assigned 3:1 to either drug or placebo. The present analysis was conducted2024-01-01T00:00:00Z2024 Jun2026-06-01T09:23:40.549Z2026-04-08T11:12:07.552ZS-EPMC110590713868360210.1001/jamaneurol.2024.0991